Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies - PubMed (original) (raw)

Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies

T M Thomson et al. J Invest Dermatol. 1988 Apr.

Free article

Abstract

Three mouse monoclonal antibodies (mAbs) recognizing antigens of human melanocytic cells were used to study a large panel of cultured normal and tumor cells and fresh tissues. Two of the monoclonal antibodies (designated TA99 and CF21) detect melanosomal antigens, whereas mAbC350 recognizes a cell surface antigen. Among cultured cells the three mAbs reacted exclusively with normal melanocytes and pigmented melanomas, but not with nonpigmented melanomas or cells of other lineage. Immunohistochemical assays using mAbTA99 and mAbCF21 on fresh-frozen sections from a large panel of normal tissues revealed a characteristic pattern of reactivity restricted to pigmented cells. mAbC350 did not react with any normal tissues. All nevi and primary melanoma specimens and 93% of metastatic melanomas were reactive with at least one of these three monoclonal antibodies. No reactivity was found with 62 nonmelanoma tumors. An inverse correlation was observed between TA99 expression and stage of tumor progression. These markers are useful for studies of melanocyte differentiation and malignant transformation, subsetting of melanocytic lesions, and identification of tumors of melanocytic origin.

PubMed Disclaimer

Cited by

TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models.
Hackett CS, Hirschhorn D, Tang MS, Purdon TJ, Marouf Y, Piersigilli A, Agaram NP, Liu C, Schad SE, de Stanchina E, Rafiq S, Monette S, Wolchok JD, Merghoub T, Brentjens RJ. Hackett CS, et al. Mol Ther Oncol. 2024 Aug 22;32(3):200862. doi: 10.1016/j.omton.2024.200862. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39308793 Free PMC article.
Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.
Yoon JH, Jung SM, Park SH, Kato M, Yamashita T, Lee IK, Sudo K, Nakae S, Han JS, Kim OH, Oh BC, Sumida T, Kuroda M, Ju JH, Jung KC, Park SH, Kim DK, Mamura M. Yoon JH, et al. EMBO Mol Med. 2013 Nov;5(11):1720-39. doi: 10.1002/emmm.201302524. Epub 2013 Oct 11. EMBO Mol Med. 2013. PMID: 24127404 Free PMC article.
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD. Yuan J, et al. Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Epub 2011 Apr 5. Cancer Immunol Immunother. 2011. PMID: 21465316 Free PMC article. Review.
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD. Yuan J, et al. Cancer Immun. 2009 Jun 5;9:5. Cancer Immun. 2009. PMID: 19496531 Free PMC article. Clinical Trial.
By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma.
Mo JS, Anderson MG, Gregory M, Smith RS, Savinova OV, Serreze DV, Ksander BR, Streilein JW, John SW. Mo JS, et al. J Exp Med. 2003 May 19;197(10):1335-44. doi: 10.1084/jem.20022041. J Exp Med. 2003. PMID: 12756269 Free PMC article.

Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies - PubMed (original) (raw)